
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
This 15-year-old girl does not appear to be in any acute distress, but her cautious gait reminds you of a person walking in the dark.






